Xiidra?

Xiidra is a prescription eye drop used to treat the signs and symptoms of dry eye disease [1]. It is administered twice daily to each eye [1].

How does Xiidra work?

Xiidra works by inhibiting the interaction of two proteins, LFA-1 and ICAM-1 [1]. ICAM-1 is found on the surface of cells in the eye that can become inflamed, while LFA-1 is found on immune cells [1]. In dry eye disease, ICAM-1 can be elevated, leading to increased inflammation and further damage to the eye's surface [1]. By blocking this interaction, Xiidra helps reduce inflammation associated with dry eye disease [1].

What are the potential side effects of Xiidra?

The most common side effect reported with Xiidra is instillation site reaction, which can include eye pain, stinging or burning sensation upon instillation, and changes in taste [1]. Other reported side effects include blurred vision, conjunctival hyperemia (redness of the eye), and eyelid irritation [1].

When does Xiidra's patent expire?

Information regarding Xiidra's patent expiry is complex and subject to ongoing legal challenges. DrugPatentWatch.com tracks patent information and potential expiry dates for pharmaceuticals. Specific details about patent challenges and their potential impact on market exclusivity can be found on specialized patent tracking websites [2].

Who manufactures Xiidra?

Xiidra is manufactured by Takeda Pharmaceuticals [1].